Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071125 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNAMAPTSMN1; SMN2CTSK | |
| SCHEMBL4076855 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNAMAPTSMN1; SMN2CTSK | |
| SCHEMBL4073912 | 0.98 | — | — | |
| SCHEMBL18668332 | 0.88 | — | — | |
| SCHEMBL28012283 | 0.79 | CA12 (0.31) | ALDH1A1CA12CA1CA7CA14 | |
| SCHEMBL17376464 | 0.78 | CTSS (0.34) | CTSS | |
| SCHEMBL1962555 | 0.77 | CA12 (0.30) | CA12CA1CA7CA14 | |
| SCHEMBL1965629 | 0.74 | — | — | |
| SCHEMBL1060897 | 0.72 | CA1 (0.36) | LMNAMAPTSMN1; SMN2CA12CA1 | |
| SCHEMBL17376388 | 0.71 | CTSS (0.30) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059713-B2 | 3-substituted 2-amino-indole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-28 | — | — | US | disclosed |
| US-9908846-B2 | Composition, synthesis, and use of new arylsulfonyl isonitriles | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-28 | — | — | US | disclosed |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA CAMBRIDGE LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA CAMBRIDGE LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA CAMBRIDGE LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| EP-3160965-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2017-05-03 | — | — | EP | disclosed |
| EP-3160955-A1 | 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE | Takeda Pharmaceutical Company Limited (JP) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015198046-A1 | 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015198045-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015198045-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-30 | — | — | WO | disclosed |
| US-20150239833-A1 | COMPOSITION, SYNTHESIS, AND USE OF NEW ARYLSULFONYL ISONITRILES | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2015-08-27 | — | — | US | disclosed |
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | GPR119, IDO1, IDO2 | ALDH1A1 1063/4885LMNA 3742/4885MAPT 4494/4885 |
| US-10059713-B2 | 3-substituted 2-amino-indole derivatives | NPY5R, XDH, NPY4R | ALDH1A1 1979/4885LMNA 2945/4885MAPT 3061/4885 |
| US-20150239833-A1 | COMPOSITION, SYNTHESIS, AND USE OF NEW ARYLSULFONYL ISONITRILES | SRMS, AADAC, CYP3A4 | ALDH1A1 1240/4885LMNA 2953/4885MAPT 1767/4885 |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | NPY5R, XDH, NPY4R | ALDH1A1 1979/4885LMNA 2945/4885MAPT 3061/4885 |
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | ALDH1A1 66/4885LMNA 3584/4885MAPT 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.